[Skip to Content]

Claim CME

Allergy and Clinical Immunology

Molecular Underpinnings of Severe Coronavirus Disease 2019

Educational Objective
To understand the molecular underpinnings of severe COVID-19

1 Credit CME

JAMA

Published Online: July 24, 2020

Editorial

Article Information and Disclosures

Robert M. Plenge, MD, PhD¹

Author Affiliations

¹Research & Early Development, Bristol Myers Squibb, Cambridge, Massachusetts

Read article on JAMA Network

Read Article Claim CME

The molecular underpinnings of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the disease it causes, coronavirus disease 2019 (COVID-19), are poorly understood. Inherited genetic variation is an important tool to disentangle cause and consequence, which in turn can generate insights to guide therapeutic interventions to prevent or treat disease. To date, little is known about genetic susceptibility to SARS-CoV-2 infection and severe forms of COVID-19.¹^,2

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Robert M. Plenge, MD, PhD, Research & Early Development, Bristol Myers Squibb, 200 Cambridgepark Dr, Cambridge, MA 02140 (robert.plenge@gmail.com).

Published Online: July 24, 2020. doi:10.1001/jama.2020.14015

Conflict of Interest Disclosures: Dr Plenge is an employee of Bristol Myers Squibb (BMS). None of the therapies mentioned in this article is a BMS product.

References

Ellinghaus D , Degenhardt F , Bujanda L , et al; Severe Covid-19 GWAS Group. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. Published online June 17, 2020. doi:10.1056/NEJMoa2020283 PubMed Google Scholar

The COVID-19 Host Genetics Initiative. Accessed July 22, 2020. www.covid19hg.org/

van der Made CI , Simons A , Schuurs-Hoeijmakers J , et al. Presence of genetic variants among young men with severe COVID-19. JAMA. Published online July 24, 2020. doi:10.1001.jama.2020.13719Google Scholar

Vabret N , Britton GJ , Gruber C , et al; Sinai Immunology Review Project. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910-941. doi:10.1016/j.immuni.2020.05.002 PubMed Google Scholar Crossref

Park A , Iwasaki A . Type I and type III interferons: induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870-878. doi:10.1016/j.chom.2020.05.008 PubMed Google Scholar Crossref

Hung IF-N , Lung K-C , Tso EY-K , et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-1704. doi:10.1016/S0140-6736(20)31042-4 PubMed Google Scholar Crossref

The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19: preliminary report. N Engl J Med. Published online July 17, 2020. doi:10.1056/NEJMoa2021436 Google Scholar

Broad Institute. Genome Aggregation Database. Accessed July 22, 2020. https://gnomad.broadinstitute.org/

Beigel JH , Tomashek KM , Dodd LE , et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19: preliminary report. N Engl J Med. Published online May 22, 2020. doi:10.1056/NEJMoa2007764 PubMed Google Scholar

Grein J , Ohmagari N , Shin D , et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-2336. doi:10.1056/NEJMoa2007016 PubMed Google Scholar Crossref

Sempowski GD , Saunders KO , Acharya P , Wiehe KJ , Haynes BF . Pandemic preparedness: developing vaccines and therapeutic. Cell. 2020;181(7):1458-1463. doi:10.1016/j.cell.2020.05.041 PubMed Google Scholar Crossref

Sanders JM , Monogue ML , Jodlowski TZ , Cutrell JB . Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-1836. doi:10.1001/jama.2020.6019 PubMed Google Scholar

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.